Zoledronate EG 5mg/100ml Infusionslösung
Sponsors
Aarhus University Hospital, Ultragenyx Pharmaceutical Inc.
Conditions
Osteoporosisosteogenesis imperfecta
Phase 3
Treatment with zoledronate subsequent to denosumab in osteoporosis 2
RecruitingCTIS2022-502621-17-00
Start: 2023-05-11Target: 1Updated: 2024-12-02
An Open-label, Randomized, Active-Controlled, Phase 3 Study of Setrusumab Compared With Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta Types I, III or IV
Active, not recruitingCTIS2023-504196-24-00
Start: 2023-10-17Target: 27Updated: 2025-11-13